Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cerebral microcirculation impairment refers to **dysfunction within the small vessels of the brain**, including arterioles, capillaries, and venules typically less than 100 μm in diameter. These vessels are essential for delivering oxygen and nutrients to meet the high metabolic demands of neural tissue. Impairment can result from endothelial dysfunction, pericyte abnormalities, morphological changes in capillaries, red or white blood cell rheology disturbances, inflammation-induced adhesion events between leukocytes and endothelium, glycocalyx damage on vessel walls,[1][3][5][7] or senescence of endothelial cells.[8] Such impairments compromise tissue oxygenation even when larger arteries remain patent. This phenomenon plays a critical role in various neurological diseases. For example: • In acute ischemic stroke—even after successful recanalization—microvascular no-reflow can prevent full reperfusion due to persistent blockages at the capillary level by deformed erythrocytes or adherent leukocytes.[3] • In neurodegenerative disorders like Alzheimer’s disease and vascular dementia,[1] chronic low-level impairments may precede neuronal loss. • After subarachnoid hemorrhage,[5] increased contractility and constriction patterns in arterioles contribute to delayed ischemia independent of large-vessel vasospasm. Because "cerebral microcirculation impairment" describes a **pathophysiological condition** rather than an individual molecular target such as a receptor or enzyme,[1][3][5] it is not considered a canonical therapeutic target itself but rather an important focus area for understanding disease mechanisms and developing new treatment strategies. If you require information about specific molecular targets involved in regulating cerebral microcirculation—such as endothelin receptors, nitric oxide synthase isoforms,[2] cystathionine β-synthase (CBS), heme oxygenase 2 (HO‑2), adhesion molecules like ICAM‑1/P-selectin—or wish to focus on one particular pathway within this system for structured data extraction purposes,[2][3] please specify further.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cerebral microcirculation impairment.